James Barder, chief executive officer at Futura Medical PLC (LON:FUM) tells Proactive Investors the company has closed the recruitment of patients in its clinical study of MED2002, a gel the company has developed for the treatment of erectile dysfunction (ED).
Barder expects the study to complete mid-summer, and to confirm that the treatment works faster than standard ED treatments like Viagra and is also safer for patients.

свернуть